Announcements Trials
Browse Landscape

Phase

Phase 1/2 13Phase 1 13Phase 3 9Phase 2 8Phase EARLY_PHASE1 1Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Malignant Solid Tumor 1

Interventions

fludarabine 9Cyclophosphamide 9pembrolizumab 5Oncolytic Virotherapy 4Nivolumab 4Cholestanetriol 26-Monooxygenase 3atezolizumab 2alpha-Synuclein 2Trastuzumab 2Influenza Vaccines 2Blood Specimen Collection 2Ascorbic Acid 2tinostamustine 1sugemalimab 1spartalizumab 1ruxolitinib 1reolysin 1pexidartinib 1methyl prednisolonate 1irinotecan sucrosofate 1fiu protein, E coli 1camrelizumab 1avelumab 1apatinib 1VTX-2337 1Temozolomide 1TAK-981 1Sorafenib 1Radiation 1RXDX-106 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × INDUSTRY × Decitabine × Clear all
NCT04076137 2019-09-03

Targeted T-cell Therapy in Solid Tumors

Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.

Phase EARLY_PHASE1 Unknown
10 enrolled
Other solid neoplasm

Malignant Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡